Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.

Jathal MK, Steele TM, Siddiqui S, Mooso BA, D'Abronzo LS, Drake CM, Whang YE, Ghosh PM.

Br J Cancer. 2019 Jun 18. doi: 10.1038/s41416-019-0496-4. [Epub ahead of print]

PMID:
31209328
2.

Galectin-1 Inhibition Induces Cell Apoptosis Through Dual Suppression of CXCR4 and Ras Pathways in Human Malignant Peripheral Nerve Sheath Tumors.

Shih TC, Fan Y, Kiss S, Li X, Deng XN, Liu R, Chen XJ, Carney R, Chen A, Ghosh PM, Lam KS.

Neuro Oncol. 2019 May 24. pii: noz093. doi: 10.1093/neuonc/noz093. [Epub ahead of print]

PMID:
31127849
3.

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC.

Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 7.

5.

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.

Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M.

Oncotarget. 2018 Oct 2;9(77):34567-34581. doi: 10.18632/oncotarget.26179. eCollection 2018 Oct 2.

6.

eIF4E Phosphorylation in Prostate Cancer.

D'Abronzo LS, Ghosh PM.

Neoplasia. 2018 Jun;20(6):563-573. doi: 10.1016/j.neo.2018.04.003. Epub 2018 May 4. Review.

7.

Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.

Shih TC, Liu R, Wu CT, Li X, Xiao W, Deng X, Kiss S, Wang T, Chen XJ, Carney R, Kung HJ, Duan Y, Ghosh PM, Lam KS.

Clin Cancer Res. 2018 Sep 1;24(17):4319-4331. doi: 10.1158/1078-0432.CCR-18-0157. Epub 2018 Apr 17.

8.

Altered expression of hepatic β-adrenergic receptors in aging rats: implications for age-related metabolic dysfunction in liver.

Shi Y, Shu ZJ, Wang H, Barnes JL, Yeh CK, Ghosh PM, Katz MS, Kamat A.

Am J Physiol Regul Integr Comp Physiol. 2018 Apr 1;314(4):R574-R583. doi: 10.1152/ajpregu.00372.2017. Epub 2017 Dec 6.

9.

Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.

D'Abronzo LS, Pan CX, Ghosh PM.

Methods Mol Biol. 2018;1655:319-334. doi: 10.1007/978-1-4939-7234-0_22.

10.

The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.

D'Abronzo LS, Bose S, Crapuchettes ME, Beggs RE, Vinall RL, Tepper CG, Siddiqui S, Mudryj M, Melgoza FU, Durbin-Johnson BP, deVere White RW, Ghosh PM.

Oncogene. 2017 Nov 16;36(46):6359-6373. doi: 10.1038/onc.2017.233. Epub 2017 Jul 24.

11.

Antagonistic regulation of cyclin expression by the bZIP transcription factors Pcr1 and Atf1 during G2/M transition.

Bandyopadhyay S, Ghosh PM, Basu S, Paul M, Alam SB, Das E, Sundaram G.

FEMS Microbiol Lett. 2017 Aug 1;364(14). doi: 10.1093/femsle/fnx132.

PMID:
28645196
12.

A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo.

Shih TC, Liu R, Fung G, Bhardwaj G, Ghosh PM, Lam KS.

Mol Cancer Ther. 2017 Jul;16(7):1212-1223. doi: 10.1158/1535-7163.MCT-16-0690. Epub 2017 Apr 10.

13.

WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Kiss Z, Ghosh PM.

Endocr Relat Cancer. 2016 Nov;23(11):T123-T134. Epub 2016 Sep 22. Review.

14.

WOMEN IN CANCER PROFILE: From physics to cancer biology and everywhere in between.

Ghosh PM.

Endocr Relat Cancer. 2016 Nov;23(11):P15-P21. Epub 2016 Sep 7. No abstract available.

PMID:
27605444
15.

Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy.

Vinall RL, Tepper CG, Ripoll AA, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, Ghosh PM, deVere White RW.

Genes Cancer. 2016 Mar;7(3-4):86-97. doi: 10.18632/genesandcancer.103.

16.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

17.

Evaluating and treating neurobehavioral symptoms in professional American football players: Lessons from a case series.

Gardner RC, Possin KL, Hess CP, Huang EJ, Grinberg LT, Nolan AL, Cohn-Sheehy BI, Ghosh PM, Lanata S, Merrilees J, Kramer JH, Berger MS, Miller BL, Yaffe K, Rabinovici GD.

Neurol Clin Pract. 2015 Aug;5(4):285-295.

18.

Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?

Sha SJ, Khazenzon AM, Ghosh PM, Rankin KP, Pribadi M, Coppola G, Geschwind DH, Rabinovici GD, Miller BL, Lee SE.

Neurocase. 2016;22(2):161-7. doi: 10.1080/13554794.2015.1080283. Epub 2015 Aug 25.

19.

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW.

PLoS One. 2015 Aug 13;10(8):e0134346. doi: 10.1371/journal.pone.0134346. eCollection 2015.

20.

Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants.

Lehmann M, Madison C, Ghosh PM, Miller ZA, Greicius MD, Kramer JH, Coppola G, Miller BL, Jagust WJ, Gorno-Tempini ML, Seeley WW, Rabinovici GD.

Neurobiol Aging. 2015 Oct;36(10):2678-86. doi: 10.1016/j.neurobiolaging.2015.06.029. Epub 2015 Jul 16.

21.

Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.

Narayanan KB, Ali M, Barclay BJ, Cheng QS, D'Abronzo L, Dornetshuber-Fleiss R, Ghosh PM, Gonzalez Guzman MJ, Lee TJ, Leung PS, Li L, Luanpitpong S, Ratovitski E, Rojanasakul Y, Romano MF, Romano S, Sinha RK, Yedjou C, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Ryan EP, Colacci A, Hamid RA, Mondello C, Raju J, Salem HK, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Kim SY, Bisson WH, Lowe L, Park HH.

Carcinogenesis. 2015 Jun;36 Suppl 1:S89-110. doi: 10.1093/carcin/bgv032. Review.

22.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

23.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, DeCarli C, Seeley WW, Jagust W.

Brain. 2015 Jul;138(Pt 7):2020-33. doi: 10.1093/brain/awv112. Epub 2015 May 6.

24.

miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.

Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M.

Mol Carcinog. 2016 May;55(5):757-67. doi: 10.1002/mc.22319. Epub 2015 Apr 11.

25.

Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.

Savoy RM, Chen L, Siddiqui S, Melgoza FU, Durbin-Johnson B, Drake C, Jathal MK, Bose S, Steele TM, Mooso BA, D'Abronzo LS, Fry WH, Carraway KL 3rd, Mudryj M, Ghosh PM.

Endocr Relat Cancer. 2015 Jun;22(3):369-86. doi: 10.1530/ERC-15-0021. Epub 2015 Mar 10.

26.

Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.

Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer AL, Rabinovici GD.

Alzheimers Res Ther. 2015 Mar 2;7(1):8. doi: 10.1186/s13195-014-0093-y. eCollection 2015.

27.

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy.

Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM, Santos M, Miller ZA, Bettcher BM, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.

Ann Neurol. 2015 Feb;77(2):338-42. doi: 10.1002/ana.24321. Epub 2014 Dec 17.

28.

Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.

Ghosh PM, Gao AC.

Endocr Relat Cancer. 2014 Oct;21(5):C11-4. doi: 10.1530/ERC-14-0387. Epub 2014 Sep 2.

PMID:
25183429
29.

The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM.

J Urol. 2015 Jan;193(1):19-29. doi: 10.1016/j.juro.2014.07.121. Epub 2014 Aug 23. Review.

30.

Practical utility of amyloid and FDG-PET in an academic dementia center.

Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, O'Neil JP, Janabi M, Huang EJ, Trojanowski JQ, Vinters HV, Gorno-Tempini M, Seeley WW, Boxer AL, Rosen HJ, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD.

Neurology. 2014 Jan 21;82(3):230-8. doi: 10.1212/WNL.0000000000000032. Epub 2013 Dec 18.

31.

The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it.

Savoy RM, Ghosh PM.

Endocr Relat Cancer. 2013 Nov 4;20(6):R341-56. doi: 10.1530/ERC-13-0364. Print 2013 Dec. Review.

32.

Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.

Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O'Neil JP, Huang Y, Miller BL, Jagust WJ, Rabinovici GD.

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):266-73. doi: 10.1136/jnnp-2013-305858. Epub 2013 Aug 21.

33.

Editorial comment.

Ghosh PM.

J Urol. 2013 Nov;190(5):1697. doi: 10.1016/j.juro.2013.05.122. Epub 2013 Aug 8. No abstract available.

PMID:
23933461
34.

Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease.

Lehmann M, Madison CM, Ghosh PM, Seeley WW, Mormino E, Greicius MD, Gorno-Tempini ML, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11606-11. doi: 10.1073/pnas.1221536110. Epub 2013 Jun 24.

35.

The changing roles of steroid nuclear receptors with prostate cancer progression.

Savoy RM, Ghosh PM.

Endocr Relat Cancer. 2013 Jul 4;20(4):C9-11. doi: 10.1530/ERC-13-0193. Print 2013 Aug.

PMID:
23744763
36.

Linking inflammation and neuroendocrine differentiation: the role of macrophage migration inhibitory factor-mediated signaling in prostate cancer.

Savoy RM, Ghosh PM.

Endocr Relat Cancer. 2013 May 21;20(3):C1-4. doi: 10.1530/ERC-13-0133. Print 2013 Jun.

PMID:
23612613
37.

Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2013 Mar;136(Pt 3):844-58. doi: 10.1093/brain/aws327. Epub 2013 Jan 28.

38.

Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.

Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM.

Endocr Relat Cancer. 2012 Nov 9;19(6):759-77. doi: 10.1530/ERC-12-0171. Print 2012 Dec.

39.

Role of β-adrenergic receptors in regulation of hepatic fat accumulation during aging.

Ghosh PM, Shu ZJ, Zhu B, Lu Z, Ikeno Y, Barnes JL, Yeh CK, Zhang BX, Katz MS, Kamat A.

J Endocrinol. 2012 Jun;213(3):251-61. doi: 10.1530/JOE-11-0406. Epub 2012 Mar 28.

40.

Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Roy M, Kung HJ, Ghosh PM.

Am J Cancer Res. 2011;1(4):542-61. Epub 2011 Mar 28.

41.

What controls PTEN and what it controls (in prostate cancer).

Ghosh PM.

Asian J Androl. 2012 Jan;14(1):130-1. doi: 10.1038/aja.2011.122. Epub 2011 Sep 26. No abstract available.

42.

Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.

Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM.

Clin Cancer Res. 2011 Oct 1;17(19):6218-28. doi: 10.1158/1078-0432.CCR-11-1548. Epub 2011 Aug 15.

43.

Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW.

Horm Cancer. 2011 Aug;2(4):224-38. doi: 10.1007/s12672-011-0076-4.

44.

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Jathal MK, Chen L, Mudryj M, Ghosh PM.

Immunol Endocr Metab Agents Med Chem. 2011 Jun;11(2):131-149.

45.

Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.

Mooso B, Madhav A, Johnson S, Roy M, Moore ME, Moy C, Loredo GA, Mehta RG, Vaughan AT, Ghosh PM.

Genes Cancer. 2010 Nov 16;1(9):927-940.

46.

Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines.

Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, Al-Bataina B, Kung HJ, Ghosh PM, Mudryj M.

Endocr Relat Cancer. 2010 Oct 5;17(4):857-73. doi: 10.1677/ERC-10-0081. Print 2010 Dec.

47.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

48.

Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM.

Clin Cancer Res. 2009 Feb 1;15(3):788-96. doi: 10.1158/1078-0432.CCR-08-1402.

49.

The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.

Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C, deVere White RW.

Am J Transplant. 2008 Dec;8(12):2668-73. doi: 10.1111/j.1600-6143.2008.02430.x. Epub 2008 Oct 6.

50.

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM.

Oncogene. 2008 Nov 27;27(56):7106-17. doi: 10.1038/onc.2008.318. Epub 2008 Sep 8.

Supplemental Content

Loading ...
Support Center